{
    "2019-08-26": [
        [
            {
                "time": "2023-10-18",
                "original_text": "Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Olumiant",
                        "Primary Endpoint",
                        "Eczema Study"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}